Regulatory news
Agency actions, classification changes, enforcement letters and scheduling decisions across the EU, EEA, UK and US. Sourced to the primary regulator.
Browse other coverage
Latest from the blog
Adolescent GLP-1 Review: Evidence Gaps
A 2026 review finds short-term benefits from adolescent GLP-1 therapy but major gaps around growth, puberty, cognition and lifelong effects.
AGGF1 and the diabetic kidney barrier
A 2026 laboratory study links AGGF1 with glomerular barrier leakage and semaglutide-related junction changes in diabetic mice.
GLP-1s in Foot and Ankle Surgery
A 2026 review found neutral or potentially better outcomes with perioperative GLP-1 use, but all three comparative studies were retrospective.
Obesity and Facial Plastic Surgery
A 2026 review links obesity, weight loss and injectable drugs to facial-surgery questions but reports no direct patient outcomes.
PYY(3-36) and semaglutide in rat MASLD
A 48-rat MASLD study found stronger liver and mitochondrial changes with PYY(3-36) plus semaglutide, but it provides no human efficacy evidence.
Retatrutide and cognition in diabetic rats
A rat study linked retatrutide with better maze performance and lower brain inflammation, but it provides no evidence of cognitive benefit in people.